Attached files
| file | filename |
|---|---|
| EX-99.2 - INVESTOR PRESENTATION - FMC CORP | investorpresentation0331.htm |
| EX-99.1 - EXHIBIT 99.1 - FMC CORP | fmcex99103312017.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________________________________________________________________
FORM 8-K
_______________________________________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15 (d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) March 31, 2017
__________________________________________________________________________
FMC CORPORATION
(Exact name of registrant as specified in its charter)
__________________________________________________________________________
Delaware | 1-2376 | 94-0479804 |
(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification No.) |
2929 Walnut Street Philadelphia, Pennsylvania | 19104 | |
(Address of principal executive offices) | (Zip Code) | |
Registrant’s telephone number, including area code: 215-299-6668
__________________________________________________________________________
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o | Written communications pursuant to Rule 425 under the Securities Act |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act |
ITEM 7.01. REGULATION FD DISCLOSURE
On March 31, 2017, FMC Corporation (the "Company") issued a press release announcing that it had signed a definitive agreement to acquire a portion of DuPont’s Crop Protection business ("Acquisition") and for DuPont to receive as consideration for the Acquisition FMC’s Health & Nutrition segment ("Divestiture") along with $1.2 billion in cash, subject to customary adjustments and other terms and conditions set forth in the definitive agreement. The Company also held a conference call and simultaneous presentation to investors to discuss the transaction.
A copy of the press release and the investor presentation are attached as Exhibit 99.1 and 99.2, respectively, to this Current Report on Form 8-K and are incorporated by reference herein.
The information set forth in this Item 7.01, including in the attached Exhibits 99.1 and 99.2, is being furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS
Exhibit No. | Description |
99.1 | Press Release of FMC Corporation, dated March 31, 2017 |
99.2 | Investor Presentation, dated March 31, 2017 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
FMC CORPORATION (Registrant) | |||
By: | /S/ PAUL W. GRAVES | ||
Paul W. Graves Executive Vice President and Chief Financial Officer | |||
Date: March 31, 2017
EXHIBIT INDEX
Exhibit No. | Description |
99.1 | Press Release of FMC Corporation, dated March 31, 2017 |
99.2 | Investor Presentation, dated March 31, 2017 |